Dupixent 在治疗大疱性类天疱疮方面显示出前景，患者达到缓解的可能性是其五倍。 Dupixent shows promise in treating bullous pemphigoid, with patients five times more likely to achieve remission.

杜皮森特在治疗皮肤疾病 - - 球状皮虫病方面显示出有前途的结果,与安慰剂组相比,获得持续缓解的成年人数是治疗患者的五倍. Dupixent showed promising results in treating bullous pemphigoid, a skin condition, with five times more adults achieving sustained remission compared to those on placebo. 这种药物还大大减少了疾病的严重程度、痒和对其他药物的需要。 The drug also significantly reduced disease severity, itch, and the need for other medications. 这可以构成首次针对该病症的定向治疗,美国和欧盟目前正在进行监管审查。 This could make Dupixent the first targeted treatment for the condition, with regulatory reviews currently underway in the US and EU.